Yes - good reminder 70FAB. Its hard to underestimate the significance of the following comment:
"Importantly, not only is the first phase 3 study that has meet primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder."
And we think there is still a chance the FDA would not approve?
This also means, I would assume, that once Trof is approved Neuren will be in the highly enviable position of having the first drug approved for any neurodevelopmental disorder. How will that be eh?
- Forums
- ASX - By Stock
- Ann: Rett Syndrome NDA accepted for Priority Review by FDA
Yes - good reminder 70FAB. Its hard to underestimate the...
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B |
Open | High | Low | Value | Volume |
$15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | $15.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.50 | 8296 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | 15.450 |
1 | 319 | 15.420 |
1 | 33 | 15.400 |
2 | 6322 | 15.370 |
1 | 5004 | 15.350 |
Price($) | Vol. | No. |
---|---|---|
15.500 | 8296 | 2 |
15.510 | 2291 | 1 |
15.540 | 2291 | 1 |
15.560 | 3500 | 1 |
15.570 | 2291 | 1 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |